Muscle-invasive bladder cancer in a cisplatin-ineligible patient who wants bladder preservation
A 74-year-old retired teacher presents with a 3-week history of painless gross hematuria. Office cystoscopy shows a 4.5 cm broad-based mass on the left lateral wall. He undergoes complete transurethral resection; pathology is high-grade urothelial carcinoma invading the muscularis propria (pT2), with focal carcinoma in situ at the resection edge. Staging CT shows no lymphadenopathy or metastases. Hydronephrosis seen on the initial scan resolved after resection. He has hypertension, type 2 diabetes with mild stocking sensory loss, and bilateral hearing aids. ECOG performance status is 1. Creatinine is 1.6 mg/dL; calculated creatinine clearance is 48 mL/min. He is adamant about avoiding a stoma if survival is not compromised and asks about bladder preservation.
1. Can this patient receive neoadjuvant cisplatin-based chemotherapy? Justify your answer using explicit eligibility criteria and describe the alternatives.
Read the worked answer
No - he is cisplatin-ineligible. Standard criteria for cisplatin-based neoadjuvant chemotherapy include ECOG 0–1, creatinine clearance ≥60 mL/min, no grade ≥2 peripheral neuropathy or hearing loss, and no NYHA class III–IV heart failure. His calculated clearance of 48 mL/min fails the renal criterion; age alone and controlled hypertension do not disqualify him. Mild sensory loss and hearing aids require documentation but are not absolute barriers if grade 1.
Options are: (1) upfront radical cystectomy with urinary diversion, which avoids chemotherapy delay; (2) bladder-preserving trimodality therapy; (3) a clinical trial; or (4) carboplatin-based neoadjuvant chemotherapy, recognizing that the phase III evidence and overall-survival benefit are much weaker than for cisplatin. Split-dose cisplatin is sometimes used for clearance 50–60 mL/min but not at 48. I would not label carboplatin/gemcitabine as equivalent to standard neoadjuvant cisplatin.
2. If he elects bladder preservation, is he a suitable trimodality candidate? Discuss tumor and host factors and the contingency plan.
Read the worked answer
Trimodality is possible but less favorable here. Favorable features: complete resection, pT2, no nodal disease, resolved hydronephrosis, ECOG 1, and a bladder that can be preserved. Adverse features: focal CIS at the resection edge and a history of obstruction, both associated with higher local recurrence; his renal function also limits cisplatin as a radiosensitizer.
A credible program requires maximal TURBT, multidisciplinary review, radiation of about 60–66 Gy with a concurrent radiosensitizer (cisplatin if tolerated, otherwise 5-FU/mitomycin or a protocol alternative), and a pre-agreed salvage cystectomy plan. He must understand that roughly one quarter to one third of patients need salvage cystectomy for nonresponse or recurrence, and that salvage is more morbid than primary cystectomy. If he is unwilling to accept salvage cystectomy, trimodality is not appropriate. I would present cystectomy as the oncologically safer default and trimodality as a reasonable alternative only with close surveillance.
3. How would you frame the recommendation and the trade-offs between radical cystectomy and trimodality for this man?
Read the worked answer
Frame it as a trade-off between oncologic certainty, recovery, and quality of life. Radical cystectomy with an ileal conduit offers the most reliable local control and avoids frequent cystoscopy and salvage surgery, but carries major perioperative risk even at ECOG 1 and age 74, a stoma, and possible metabolic and renal issues. Trimodality preserves the native bladder in most patients and avoids a stoma, but requires rigorous follow-up, may compromise salvage options, and has a real failure rate.
I would quote 5-year overall survival in the range of 50–60% for both approaches in well-selected pT2 patients, while emphasizing that the trimodality data come from selected patients and that his CIS and prior hydronephrosis lower the chance of success. A shared decision should include his willingness to undergo salvage cystectomy and his tolerance of surveillance. If he prioritizes avoiding a stoma and accepts salvage, proceed with trimodality; if he prioritizes oncologic certainty, proceed with cystectomy.